Privi Speciality Chemicals Ltd

- No immediate equity dilution is planned for the INR1,200 crores capex; funding will mainly come from internal accruals and bank borrowings. - Debt-to-EBITDA ratio is currently around 1.6x and is targeted to be maintained below 2.5x as a guideline for future borrowings. - The company intends to keep the debt within healthy limits and does not foresee the need for equity dilution at this point. - The CFO will take a call if needed on any equity dilution, but as of now, it is not expected. - Overall, the financing strategy leans heavily on internal accruals and moderate borrowing without equity dilution.

- The company has planned a total capex of INR 1,200 crores over 3 years (FY26 to FY28), split as: - Phase 1: INR 300 crores - Phase 2: INR 600 crores - Phase 3: INR 300 crores - This capex aims to support growth beyond 54,000 metric tons capacity and achieve INR 5,000 crores revenue by FY28-29. - Capex includes new product facilities expected to come on stream by Q1 FY28, with potential stabilization issues for a quarter. - Additional facility and automation required for a new corn cob product plant targeting 20,000-ton scale by ’27-’28. - Joint venture (Prigiv) with Givaudan plans an investment of INR 50 crores for capacity expansion, funded by equity (Privi 51%, Givaudan 49%). - Focus on technology development and scaling up specialty molecules is part of the strategic investment roadmap. - Capex funding is primarily through internal accruals and bank borrowing; equity dilution currently not anticipated.

- FY '28 will be a transition year for growth, with a material scale-up expected in FY '29. (Page 18) - Volume growth for the coming financial year is expected to be around 7%, with potential to be higher (possibly between 11%-15%) due to new projects starting. (Page 6 & 11) - Capacity expansion will increase from 48,000 metric tons to 54,000 metric tons by March-April 2027, maintaining around 90% utilization. (Page 12) - Further expansion includes an additional 18,000 metric tons capacity focused on multi-speciality and speciality products beyond existing products. (Page 12) - A 20% CAGR growth target is maintained, with a roadmap to achieve INR5,000 crore revenue by FY '29. (Pages 6, 11) - New product facility expected to be commissioned around Q1 FY '28 with potential stabilization issues for a quarter. (Page 16 & 18) - Growth beyond volume is expected from high-margin value-added and speciality products. (Page 6, 14)

- FY '28 is expected to be a transition year in terms of growth, with some stabilization issues as new product facilities come on stream (Q1 FY '28). - FY '29 is anticipated to witness a material scale-up in revenue growth, catapulting the company to the next level. - EBITDA margins have been consistently above 20%, with over 25% achieved in the past three quarters; expected to sustain 20%+ margins going forward. - Profit after tax (PAT) showed remarkable growth of 84% YoY for 9 months ended Dec '25. - Joint venture Prigiv is progressing well, expected to be net profit-positive next year, contributing additionally. - The company aims for INR 5,000 crores revenue by FY '29 with corresponding profitable growth. - Operational efficiencies and optimized capacity expansions underpin margin improvements. - Capex of INR 1,200 crores over 3 years supports scaling and margin enhancement without immediate equity dilution.

- The transcript does not explicitly state the current or expected order book or pending orders. - Rohit Nagraj asked about revenue visibility and contracts for new products; Sanjeev Patil responded that they seek customer approvals as projects progress and get indicative commitments then, but specific order book details are not disclosed. - Narayan Iyer mentioned that contracts are typically 70% on contract and 30% spot market. - Overall, business outlook suggests a positive demand environment with 7%-15% volume growth expected in the next financial year, supported by capacity expansions. - The company maintains a strong pipeline aligned with their INR 1,200 crore capex and 3-phase expansion plan to reach INR 5,000 crore revenues by FY 28-'29. - No detailed quantification of order book was provided in the call.